CONSUN PHARMA (01681) released its interim results, with shareholders profit amounting to 595 million yuan, an increase of 19.5% year-on-year. Sales of kidney-related products grew approximately 18.1% compared to the same period last year.

CONSUN PHARMA (01681) released its performance results for the six months ended June 30, 2026. The group achieved revenue of RMB 1.785 billion during this period, representing a year-on-year increase of 13.8%. The profit attributable to equity shareholders was RMB 595 million, an increase of 19.5% compared to the previous year; basic earnings per share were RMB 0.71; and a mid-term dividend of HKD 0.38 per share is proposed. By product category, sales of nephrology products increased by approximately 18.1% compared to the same period in 2025, maintaining its market leadership. Sales of the women's and children's products and liver and gallbladder products increased by approximately 9.1% and 233.7%, respectively. The overall revenue growth for the group is primarily attributed to its continued efforts to expand its national sales network and improve product market coverage. In the first half of 2026, the groups gross profit was RMB 1.452 billion, an increase of about 20.1% compared to RMB 1.209 billion in the same period of 2025. The growth in gross profit was mainly due to increased sales. In the first half of 2026, the group's average gross profit margin was approximately 81.4%, an increase of 4.3 percentage points from 77.1% in the same period of 2025, mainly due to the group's improvement of supplier management systems and continuous enhancement of production operational efficiency, coupled with a decline in the market procurement prices of core raw materials.